Inotersen, sold under the brand name Tegsedi, is a 2'-O-(2-methoxyethyl) (2'-MOE) antisense oligonucleotide medication used for the treatment of nerve damage in adults with hereditary transthyretin-mediated amyloidosis. The sequence is 5'-TCTTG GTTACATGAA ATCCC-3', where C is 5-methylcytidine, and the first and third section (bases 1-5 and 16–20, separated from the middle section by spaces) are MOE-modified (i.e. inotersen is a gapmer).
Inotersen, sold under the brand name Tegsedi, is a 2'-O-(2-methoxyethyl) (2'-MOE) antisense oligonucleotide medication used for the treatment of nerve damage in adults with hereditary transthyretin-mediated amyloidosis. The sequence is 5'-TCTTG GTTACATGAA ATCCC-3', where C is 5-methylcytidine, and the first and third section (bases 1-5 and 16–20, separated from the middle section by spaces) are MOE-modified (i.e. inotersen is a gapmer).
The most common side effects are injection site reactions (redness, swelling, bleeding, pain, rash, and itching at the injection site), nausea, headache, tiredness, low platelet counts, and fever.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).